168 related articles for article (PubMed ID: 37631039)
1. Identification of Drug Targets and Their Inhibitors in
Ali H; Samad A; Ajmal A; Ali A; Ali I; Danial M; Kamal M; Ullah M; Ullah R; Kalim M
Pharmaceuticals (Basel); 2023 Aug; 16(8):. PubMed ID: 37631039
[No Abstract] [Full Text] [Related]
2. Decrypting the multi-genome data for chimeric vaccine designing against the antibiotic resistant Yersinia pestis.
Sarfraz A; Qurrat-Ul-Ain Fatima S; Shehroz M; Ahmad I; Zaman A; Nishan U; Tayyab M; Sheheryar ; Moura AA; Ullah R; Ali EA; Shah M
Int Immunopharmacol; 2024 May; 132():111952. PubMed ID: 38555818
[TBL] [Abstract][Full Text] [Related]
3. Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague.
Zauberman A; Tidhar A; Levy Y; Bar-Haim E; Halperin G; Flashner Y; Cohen S; Shafferman A; Mamroud E
PLoS One; 2009 Jun; 4(6):e5938. PubMed ID: 19529770
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic and innate immune responses to Yersinia pestis in the lymph node during bubonic plague.
Comer JE; Sturdevant DE; Carmody AB; Virtaneva K; Gardner D; Long D; Rosenke R; Porcella SF; Hinnebusch BJ
Infect Immun; 2010 Dec; 78(12):5086-98. PubMed ID: 20876291
[TBL] [Abstract][Full Text] [Related]
5. Shift from primary pneumonic to secondary septicemic plague by decreasing the volume of intranasal challenge with Yersinia pestis in the murine model.
Olson RM; Anderson DM
PLoS One; 2019; 14(5):e0217440. PubMed ID: 31121001
[TBL] [Abstract][Full Text] [Related]
6. Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin.
Rosenzweig JA; Brackman SM; Kirtley ML; Sha J; Erova TE; Yeager LA; Peterson JW; Xu ZQ; Chopra AK
Antimicrob Agents Chemother; 2011 Nov; 55(11):5034-42. PubMed ID: 21859946
[TBL] [Abstract][Full Text] [Related]
7. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
[TBL] [Abstract][Full Text] [Related]
8. In Silico Prediction of New Inhibitors for Kirsten Rat Sarcoma G12D Cancer Drug Target Using Machine Learning-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulation Approaches.
Ajmal A; Danial M; Zulfat M; Numan M; Zakir S; Hayat C; Alabbosh KF; Zaki MEA; Ali A; Wei D
Pharmaceuticals (Basel); 2024 Apr; 17(5):. PubMed ID: 38794122
[TBL] [Abstract][Full Text] [Related]
9. Invasiveness of the Yersinia pestis ail protein contributes to host dissemination in pneumonic and oral plague.
Zhang Y; Ying X; He Y; Jiang L; Zhang S; Bartra SS; Plano GV; Klena JD; Skurnik M; Chen H; Cai H; Chen T
Microb Pathog; 2020 Apr; 141():103993. PubMed ID: 31988008
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for the control of Yersinia pestis infections. Recommendations from the CDC.
White ME; Gordon D; Poland JD; Barnes AM
Infect Control; 1980; 1(5):324-9. PubMed ID: 6904395
[TBL] [Abstract][Full Text] [Related]
11. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
Louie A; Heine HS; VanScoy B; Eichas A; Files K; Fikes S; Brown DL; Liu W; Kinzig-Schippers M; Sörgel F; Drusano GL
Antimicrob Agents Chemother; 2011 Feb; 55(2):822-30. PubMed ID: 21115791
[TBL] [Abstract][Full Text] [Related]
12. [Yersinia pestis and plague - an update].
Stock I
Med Monatsschr Pharm; 2014 Dec; 37(12):441-8; quiz 449. PubMed ID: 25643450
[TBL] [Abstract][Full Text] [Related]
13. The Yersinia pestis GTPase BipA Promotes Pathogenesis of Primary Pneumonic Plague.
Crane SD; Banerjee SK; Eichelberger KR; Kurten RC; Goldman WE; Pechous RD
Infect Immun; 2021 Jan; 89(2):. PubMed ID: 33257531
[No Abstract] [Full Text] [Related]
14. [Yersinia pestis as a dangerous biological weapon].
Grygorczuk S; Hermanowska-Szpakowicz T
Med Pr; 2002; 53(4):343-8. PubMed ID: 12474416
[TBL] [Abstract][Full Text] [Related]
15. Development of a PCR-lateral flow assay for rapid detection of Yersinia pestis, the causative agent of plague.
Singh R; Pal V; Kumar M; Tripathi NK; Goel AK
Acta Trop; 2021 Aug; 220():105958. PubMed ID: 34004173
[TBL] [Abstract][Full Text] [Related]
16. Yersinia pestis Exploits Early Activation of MyD88 for Growth in the Lungs during Pneumonic Plague.
Olson RM; Dhariwala MO; Mitchell WJ; Anderson DM
Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30642901
[No Abstract] [Full Text] [Related]
17. Machine Learning-based Virtual Screening for STAT3 Anticancer Drug Target.
Wadood A; Ajmal A; Junaid M; Rehman AU; Uddin R; Azam SS; Khan AZ; Ali A
Curr Pharm Des; 2022; 28(36):3023-3032. PubMed ID: 35909285
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.
Erova TE; Rosenzweig JA; Sha J; Suarez G; Sierra JC; Kirtley ML; van Lier CJ; Telepnev MV; Motin VL; Chopra AK
Clin Vaccine Immunol; 2013 Feb; 20(2):227-38. PubMed ID: 23239803
[TBL] [Abstract][Full Text] [Related]
19. Yersinia pestis: still a plague in the 21st century.
Josko D
Clin Lab Sci; 2004; 17(1):25-9. PubMed ID: 15011977
[TBL] [Abstract][Full Text] [Related]
20. In-silico approach of identifying novel therapeutic targets against Yersinia pestis using pan and subtractive genomic analysis.
Islam J; Sarkar H; Hoque H; Hasan MN; Jewel GMNA
Comput Biol Chem; 2022 Dec; 101():107784. PubMed ID: 36375370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
